Intangible and Other Assets, Net - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, amortization expense	$ 25,000	$ 218,000	$ 1,700,000
Finite lived intangible assets, Weighted average amortization period	17 years	17 years	14 years 10 months 24 days
Finite lived intangible assets, estimated future amortization expense year one	28,000
Finite lived intangible assets, estimated future amortization expense year two	28,000
Finite lived intangible assets, estimated future amortization expense year three	28,000
Finite lived intangible assets, estimated future amortization expense year four	28,000
Finite lived intangible assets, estimated future amortization expense year five	28,000
Finite lived intangible assets, estimated future amortization expense after year five	828,000
Capitalized patent and license costs
Finite-Lived Intangible Assets [Line Items]
Impairment of the carrying value of intangible asset		5,200,000	312,000.0
Ridaforolimus, the Company's investigational oral mTOR inhibitor
Finite-Lived Intangible Assets [Line Items]
Impairment of the carrying value of intangible asset		$ 4,800,000